Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of cadonilimab in combination with bevacizumab and standard chemotherapy as first Line therapy in unresectable pleural mesothelioma.
Histologically confirmed pleural malignant mesothelioma not eligible for curative surgery
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
No previous systemic anti-tumor treatment for advanced/metastatic disease
Measurable disease as per mRECIST v1.1 for assessment of response in malignant pleural mesothelioma.
Primitive peritoneal, pericardial and tunica vaginalis testis mesothelioma.
Active, untreated central nervous system (CNS) metastasis.
Use of Chinese herbal medicine or immunomodulatory agents with anti-tumor indications within 14 days prior to the first dose of study treatment.
Known active autoimmune diseases.